Evidence map›Paper›PMID 26809559›Full record

ArticleBMC infectious diseases2016

Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy.

Sara Gianella, Christine C Ginocchio, Eric S Daar, Michael P Dube, Sheldon R Morris

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Longitudinal Viral Dynamics in Semen During Early HIV Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Sara GianellaUniversity of California San Diego, 500 Gilman Drive MC 0679, La Jolla, CA, 92093-0679, USA. gianella@ucsd.edu.
Christine C GinocchioNorth Shore-LIJ Health System, Lake Success, NY, USA. cginocch@gmail.com.
Eric S DaarLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. edaar@labiomed.org.
Michael P DubeUniversity of Southern California Keck School of Medicine, 1300 N. Mission Road, Suite 349, Los Angeles, CA 91106, CA, USA. mdube@med.usc.edu.
Sheldon R MorrisUniversity of California San Diego, 500 Gilman Drive MC 0679, La Jolla, CA, 92093-0679, USA. shmorris@ucsd.edu.
University of California, San Diego · USHarbor–UCLA Medical Center · USNorthwell Health · USUniversity of Southern California · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
Transmission ProbabilityP01AI074621 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2008 to 2012
$23.1M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
San Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
WOMEN'S HEALTH AGENDAU01AI027670 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 1988 to 2006
$13.7M
NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1TR000100NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NIAID NIH HHS 7-UM1 AI068636-07NIAID NIH HHS AI043638NIAID NIH HHS AI047745NIAID NIH HHS AI077304NIAID NIH HHS AI080353NIAID NIH HHS AI100665NIAID NIH HHS AI27670NIAID NIH HHS AI306214NIAID NIH HHS AI36214NIAID NIH HHS AI43638NIAID NIH HHS AI69432NIAID NIH HHS AI74621NIAID NIH HHS K24 AI100665NIAID NIH HHS P01 AI074621NIAID NIH HHS P30 AI027763NIAID NIH HHS P30-AI027763NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R21 AI047745NIAID NIH HHS R21 AI077304NIAID NIH HHS R21 AI080353NIAID NIH HHS R24 AI106039NIAID NIH HHS R24AI106039NIAID NIH HHS R56 AI047745NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI043638NIAID NIH HHS U01 AI069432NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069432NIGMS NIH HHS GM093939NIGMS NIH HHS R01 GM093939NIMH NIH HHS MH083552NIMH NIH HHS MH101012NIMH NIH HHS MH62512NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH083552NIMH NIH HHS R01 MH101012
6 · The paper itself

Abstract

backgroundEpstein Barr virus (EBV) and human papillomavirus (HPV) can co-exist in pharyngeal and cervical malignancies. However, the natural history and factors associated with persistent HPV infection among HIV-infected men who have sex with men (MSM) are unclear.

methods131 HIV-infected MSM were followed for 48 weeks and screened for multiple co-infections, including seminal EBV DNA and high risk (HR)-HPV messenger RNA (mRNA) at several sites (semen, anal, pharynx). Primary analysis tested if seminal EBV shedding was associated with increased prevalence of HR-HPV at baseline using univariate tests and multivariable logistic regression. In participants with detectable anal HR-HPV at baseline, we tested if presence of seminal EBV shedding at baseline was also predictive of reduced HR-HPV clearance by log-rank test (over 48 weeks of follow-up).

resultsBaseline prevalence of HR-HPV was: anal 44% (N = 54/121); pharynx 3.8% (N = 5/131); semen 7.1% (N = 7/98). Seminal EBV shedding was present in 28% of participants and was associated with more than double the prevalence of detectable anal HR-HPV mRNA (71.4% for EBV shedders versus 33.3% for non-shedders, p < 0.01). In participants with detectable anal HR-HPV at baseline, we found increased persistence of HR-HPV over 48 weeks of follow-up (measured as time to first negative HR-HPV test in the EBV shedding group (p < 0.01).

conclusionsSeminal EBV shedding was associated with an increased risk of having detectable anal HR-HPV in a cohort of HIV-infected MSM on suppressive ART. Future studies should examine if co-infection with EBV and HR-HPV may act synergistically in pathogenesis of anal cancer in HIV-infected individuals.

Indexed as

Herpesvirus 4, HumanPapillomaviridaeAdultAnti-HIV AgentsCoinfectionEpstein-Barr Virus InfectionsFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedPapillomavirus InfectionsPharynxPrevalenceProspective StudiesAnti-HIV Agents

Identifiers

PMID26809559
PMCPMC4727320
OpenAlexW2268713379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.